Open Access

Field evaluation of a rapid diagnostic test (Parascreen™) for malaria diagnosis in the Peruvian Amazon

  • Jorge Bendezu1,
  • Angel Rosas1, 2,
  • Tanilu Grande1, 2,
  • Hugo Rodriguez2,
  • Alejandro Llanos-Cuentas1, 2,
  • Jorge Escobedo3 and
  • Dionicia Gamboa1, 4Email author
Malaria Journal20109:154

https://doi.org/10.1186/1475-2875-9-154

Received: 28 February 2010

Accepted: 7 June 2010

Published: 7 June 2010

Abstract

Background

The rapid diagnostic tests for malaria (RDT) constitute a fast and opportune alternative for non-complicated malaria diagnosis in areas where microscopy is not available. The objective of this study was to validate a RDT named Parascreen™ under field conditions in Iquitos, department of Loreto, Peru. Parascreen™ is a RDT that detects the histidine-rich protein 2 (HRP2) antigen from Plasmodium falciparum and lactate deshydrogenase from all Plasmodium species.

Methods

Parascreen™ was compared with microscopy performed by experts (EM) and polymerase chain reaction (PCR) using the following indicators: sensitivity (Se), specificity (Sp), positive (PV+) and negative predictive values (PV-), positive (LR+) and negative likehood ratio (LR-).

Results

332 patients with suspected non-complicated malaria who attended to the MOH health centres were enrolled between October and December 2006. For P. falciparum malaria, Parascreen™ in comparison with EM, had Se: 53.5%, Sp: 98.7%, PV+: 66.7%, PV-: 97.8%, LR+: 42.27 and LR-: 0.47; and for non-P. falciparum malaria, Se: 77.1%, Sp: 97.6%, PV+: 91.4%, PV-: 92.7%, LR+: 32.0 and LR-: 0.22. The comparison of Parascreen™ with PCR showed, for P. falciparum malaria, Se: 81.8%, Sp: 99.1%, PV+: 75%, PV-: 99.4, LR+: 87.27 and LR-: 0.18; and for non-P. falciparum malaria Se: 76.1%, Sp: 99.2%, PV+: 97.1%, PV-: 92.0%, LR+: 92.51 and LR-: 0.24.

Conclusions

The study results indicate that Parascreen™ is not a valid and acceptable test for malaria diagnosis under the field conditions found in the Peruvian Amazon. The relative proportion of Plasmodium species, in addition to the genetic characteristics of the parasites in the area, must be considered before applying any RDT, especially after the finding of P. falciparum malaria parasites lacking pfhrp2 gene in this region.

Background

Malaria affects people in more than 108 countries around the world, with nearly 243 million estimated cases and nearly 863 thousands of deaths reported in the last year [1]. Despite a reduction of the incidence by up to 40% during the last four years in Peru, malaria due to Plasmodium falciparum and Plasmodium vivax remains an important public health problem, especially in the Amazon region where more than 70% of the cases of the country are reported [2].

In malaria patients, a prompt and accurate diagnosis is the key for effective disease management, in order to reduce the probability of complications and mortality. The two diagnostic approaches currently in use, clinical diagnosis and microscopy, do not allow a satisfactory diagnosis of malaria. Clinical diagnosis, the most widely used, is unreliable because the symptoms of malaria are non-specific [3, 4]. Diagnosis by microscopy, the established method for laboratory confirmation of malaria, presents technical and personnel requirements that often cannot be achieved [48], particularly in many areas of the Amazon region, far away from the main cities, where the population is widely dispersed and few health centres exist. Because of the reasons mentioned above and with the appearance of severe vivax malaria cases in different countries around the world in the last years [9], it is imperative to have a rapid and appropriate diagnosis method for malaria in Peru.

Rapid diagnostic tests for malaria (RDT) offer a good alternative with the advantage that it is an easy and rapid method, which requires minimum training [6, 7, 1012]. The evaluation of different RDTs in many places in the last decade has demonstrated high sensitivity and specificity, compared with expert microscopy diagnosis as gold standard [3, 6, 8, 10, 11, 1315]. However, it was also observed that the same RDT used in different places showed different results, which is probably related to different conditions found in these places (temperature, humidity, characteristics of the malaria parasites, etc.). This is one of the reasons why initiatives like the WHO/TDR/FIND malaria RDT product testing programme, evaluating different RDTs under standardized conditions; could guide the malaria programmes in different countries to select the best RDT for a specific region [16].

Furthermore, the recent finding of P. falciparum field isolates lacking expression of the pfhrp2 gene in the Peruvian Amazon region should also be taken into account to choose the proper RDT for this region [17].

For more sensitive malaria detection, several polymerase chain reaction (PCR) assays have also been developed, and are mainly used in epidemiological studies [18]. The major advantage of this approach is the capability to detect malaria parasites in patients with low levels of parasitaemia, (five or less parasites per μL of blood), including sub-patent malaria infections, which can be detected with 100% of sensitivity and specificity. However, the difficulty in acquiring and maintaining the required technical skills is the main disadvantage of this technique [7, 8, 14].

Parascreen™ is a RDT that has been assessed in different studies in Asian and African countries [1921], where the test performed well under field conditions. In the present study Parascreen™ was evaluated in different communities around Iquitos, department of Loreto, Peru, and compared its performance with expert microscopy and PCR.

Methods

Study design and specimens

Patients with history of fever with or without chills, sweating and headache (clinical symptoms suspicious of malaria), and with no history of anti-malarial treatment during the last two weeks, were enrolled through a passive malaria case detection in six health facilities around Iquitos (Department of Loreto) in the Peruvian Amazon, between October and December 2006. The minimum required sample size for this study was determined to be 96 confirmed malaria cases and 96 non-malaria cases, assuming a sensitivity and specificity at 90% with a precision of 6%, at a 95% confidence interval.

Blood samples for thick and thin blood films, for the Parascreen™ test and for PCR (collected on filter paper, 3 MM), were collected by finger-prick. Diagnosis procedures, including microscopy, Parascreen™ and PCR, were carried out by different staff blinded to each other result.

Expert microscopy

This procedure was carried out in the six health centres, located in rural areas, using standard protocols according to the Peruvian national guidelines [22]. Thick smears prepared with a finger-prick sample were stained with 10% Giemsa and examined using a microscope with a 100 × oil immersion objective. The parasite density was expressed as the number of parasites/μl of blood, by using an average number of leucocytes per microlitre of blood of 6,000 (according to the Peruvian national guidelines) for the calculations (number of counted parasites, multiplied by 6,000, divided by the number of counted leucocytes, by counting a total of ≥200 and ≥500 leucocytes if the number of parasites per microscope field is > 10 and < 10, respectively) [22]. The results were recorded together with clinical and epidemiological data from each patient. For the quality control, 10% of the slides were examined by a second expert microscopist at the reference laboratory (Centro de Salud San Juan) in Iquitos.

Parascreen™

Parascreen™(Zephyr Biomedical Systems, lot: 101051) is a RDT that detects the histidine-rich protein 2 antigen of P. falciparum and the lactate deshydrogenase of Plasmodium. The reactive strip has three different detection lines: a distal line with non-specific antibodies that recognize HRP-2 P. falciparum; a middle line with specific antibodies that recognize the lactate deshydrogenase enzyme of the "pan malaria group" (P. falciparum and non -P. falciparum), and a proximal line with antibodies that capture the excess of conjugate and therefore function as an assay control.

The RDT was performed and results were interpreted according to the manufacturer's instructions [23]. Briefly, only one pink-purple line in the proximal area (control line) means negative for malaria; one pink-purple line in the middle area, in addition to the control line, means non-P. falciparum infection; one pink-purple line, in addition to the previous two bands, means P. falciparum infection. When the control line did not appear or the interpretation was doubtful, the test was repeated.

PCR procedures

The parasite DNA was extracted from the filter paper using the Chelex - 100 method (Bio-Rad Laboratories, Hercules, CA). Filter paper blood spots prepared with approximately 20 μL of blood were cut into pieces of approximately 5 mm2, and incubated with 20 μL of 0.05% saponin (Sigma™) at room temperature for four hours. Then 10 μL of 20% Chelex - 100 solution was added, and the sample was incubated for 10 minutes at 95°C, followed by a centrifugation at 11,000 g. The supernatant (DNA) was transferred into a new tube and stored at -20°C until use. The DNA was amplified by a semi-nested multiplex PCR method, as described by Rubio et al [24], The PCR products were analyzed in a 2% agarose gel (analytic grade, Promega™) with a 100 pb DNA marker (Promega™), using ethidium bromide staining (0.5 μg/ml) and a data image Analyzer with UV trans-illuminator (Gel Doc option, BioRad™).

Data analysis

All quantitative data were encoded in a data sheet and processed using SPSS 12.0 for Windows and XLSTAT 2007. A 2 × 2 table was created to analyze association values between the three diagnosis methods. The following indicators for Parascreen™ RDT detection were calculated, using either PCR or expert microscopy (EM) as the gold standard: (95% CI): sensitivity (Se), specificity (Sp), positive (PV+) and negative predictive values (PV-), positive (LR+) and negative likehood ratio (LR-). All non-P falciparum infections were confirmed to be P. vivax by microscopy and PCR (no detection of P. malariae and P. ovale).

Ethical considerations

This study was approved by the Ethics Review Board of the Universidad Peruana Cayetano Heredia, Lima, Peru (Code SIDISI: 051675). Before any sample was taken, the participants signed an informed consent.

Results

A total of 332 symptomatic malaria patients were included in this study. The mean age was 32 ± 16 years. The results of EM, PCR and Parascreen™ are shown in Table 1. With EM, there were 234 negative and 98 positive slides, 83 P. vivax infections with parasite density between 24 to 17,385 parasites/μl (2,662,323 ± 3,083.7) and 15 P. falciparum infections with parasite density between 36 to 36,457 parasites/μl (4,622.8 ± 8,920). With PCR, there were 232 negative and 100 positive samples, 88 P. vivax, 11 P. falciparum and one mixed infection (P. falciparum and P. vivax). With Parascreen™, there were 250 negative and 82 positive samples, 70 P. vivax infections and 12 P. falciparum.
Table 1

Parascreen™ diagnosis results and comparison with diagnosis by PCR and EM.

Results by Parascreen™

PCR

EM

  

Negative

P.vivax

P.falciparum

Mixed

Negative

P.vivax

P.falciparum

Negative

250

230

19

1

0

230

16

4

non-P. falciparum

70

1

67

1

1

3

64

3

P. falciparum

12

1

2

9

0

1

3

8

Total

332

232

88

11

1

234

83

15

EM was first compared to PCR as gold standard, showing the following indicators: for detection of P. falciparum malaria, Se: 90.9% and Sp: 96.8%; and for non-P. falciparum malaria, Se: 90.9% and Sp: 98.76%. A discrepancy in species diagnosis between PCR and EM diagnosis was observed in five cases (including one mixed infection detected by PCR). Furthermore, four cases with negative diagnosis by EM were detected positive by PCR, and two cases with negative results by PCR tested positive by EM.

Table 2 presents the calculated indicators when Parascreen™ was compared with EM and PCR. When EM was used as gold standard, Parascreen™ had, for P. falciparum detection the following indicators: Se: 53.5%, Sp: 98.7%, PV+: 66.7%, PV-: 97.8%, LR+: 42.27 and LR-:0.47; and for non-P. falciparum malaria Se: 77.1%, Sp: 97.6%, PV+: 91.4%, PV-: 92.7%, LR+: 32.0 and LR-: 0.22. P. falciparum diagnosis using Parascreen™ had a high proportion of false negatives 46.7% [95% CI (24.8-69.9)].
Table 2

Comparative indicators of Parascreen™, when using PCR and EM as gold standards.

gold standard

Results by Parascreen™

 

Plasmodium

Species

Sensitivity

[%(95%CI)] a

Specificity

[%(95%CI)]

PPV b

[%(95%CI)]

PPN c

[%(95%CI)]

Likehood ratio

      

Positive test

Negative test

EM

non-P. falciparum

77.1

(67.0-84.4)

97.6

(94.8-98.9)

91.4

(82.5-96.0)

92.7

(89.0-95.3)

32

0.22

 

P. falciparum

53.5

(30.1-75.2)

98.7

(96.8-99.5)

66.7

(39.1-86.2)

97.8

(95.6-98.9)

42.27

0.47

PCR

non-P. falciparum

76.1

(66.3-83.8)

99.2

(97.0-99.8)

97.1

(90.0-99.2)

92

(88.1-94.7)

92.51

0.24

 

P. falciparum

81.8

(52.3-94.9)

99.1

(97.3-99.7)

75

(46.8-91.1)

99.4

(97.7-99.8)

87.27

0.18

a.- Confidence interval at 95%.

b.- Positive predictive value.

c.- Negative predictive value.

When PCR was used as gold standard, Parascreen™ showed a better sensitivity for detection of P. falciparum and P. vivax infections. For P. falciparum, the indicators were: Se: 81.8%, Sp: 99.1%, PV+: 75%, PV-: 99.4, LR+: 87.27 and LR-: 0.18. For non-P. falciparum the following indicators were observed: Se: 76.1%, Sp: 99.2%, PV+: 97.1%, PV-: 92.0%, LR+: 92.51 and LR-: 0.24.

Parascreen™ had a low sensitivity (12.5%) for detection of P. vivax infections at parasite densities below 99 parasites/μl, which increased for the detection of parasite densities between 99 and 500 parasites/μl (sensitivity of 60%). For P. falciparum infections, parasite densities below 1,000 parasites/μl were detected with less sensitivity (25%) than parasite densities > 1,000 parasites/μl (sensitivity between 66.7% and 75.0%) (Table 3).
Table 3

Parascreen™ sensitivity, PPV and False-negative proportion at different parasitaemia determined by expert microscopy.

Parascreen™

Parasite

density

(parasites/ul)

N

(Number of samples)

Sensitivity

[%(95%CI)]

PPV

[%(95%CI)]

False - negative

proportion

[%(95%CI)]

P. vivax

     
 

1-99

8

12.5 (2.2-47.1)

100

87.5 (52.9-97.8)

 

100-499

15

60.0 (35.7-80.2)

100

40.0 (19.8-64.3)

 

500-999

13

84.6 (57.8-95.7)

100

15.4 (4.3-42.2)

 

1,000-4,999

35

91.4 (77.6-97.0)

100

8.6 (3.0-22.4)

 

+ 5,000

12

91.7 (64.6-98.5)

100

8.3 (1.5-35.4)

P. falciparum

     
 

1-999

5

25.0 (4.6-69.9)

100

75.0 (30.1-95.4)

 

1,000-1,999

3

66.7 (20.8-93.9)

100

33.3 (6.1-79.2)

 

2,000-4,999

4

75.0 (30.1-95.4)

100

25.0 (4.6-69.9)

 

+ 5,000

3

66.7 (20.8-93.9)

100

33.3 (6.1-79.2)

a,b.- Abbreviations as in Table 2

Discussion

This study, conducted in Iquitos, Department of Loreto, showed an unacceptable performance of Parascreen™ for malaria diagnosis under the field conditions found in the Peruvian Amazon. Even though the RDT was of simple training and use for the local health staff, it showed variable indicators when compared with EM and PCR, depending on the Plasmodium species (P. vivax or P. falciparum) and parasitaemia of the infections.

In this study, Parascreen™ sensitivity for malaria infection was lower than the 100% sensitivity obtained in a validity assessment done by Zephyr Biomedical System [23]. In studies performed in Kenya [19] and India [21] the sensitivity values were 94.0% and 96.3% respectively. A study carried out in Ethiopia [20] describes similar results to the ones obtained in this study. In comparison with other RDTs, Parascreen™ sensitivity for P. falciparum infection was lower than that obtained with OptiMAL™ which detects Plasmodium lactate deshydrogenase. HRP2-based RDTs such as Parascreen™ have also been evaluated in various studies in South American countries [2528]. The sensitivity and specificity for P. falciparum and P. vivax infections observed in this study were better than those reported with AMRAD fast test ICT P.f/P v in Peru [6], and similar to those obtained with Binax NOW™ fast test ICT P.f/P.v in Colombia, but lower than those observed with NOW-Malaria-ICT RDT in an evaluation study in Colombia [18] and in various other studies of OptiMAL IT [6, 10, 11, 13, 26].

The likelihood ratio (Lr) is independent of the prevalence of the disease in the population, and can be used to determine the accuracy of positive or negative test results [29]. In this study, high likelihood ratios of a positive test (Lr+), above 10, were found for P. falciparum and non-P. falciparum infections; confirming that patients with positive tests would have a high probability to be infected.

On the contrary, the observed likelihood ratios of a negative Parascreen™ test (Lr-), with values above 0.1, indicated a high risk of error when excluding malaria diagnosis in patients with negative tests. Similar findings were found in an evaluation study of OptiMAL™ in febrile travelers returning from malaria endemic countries, especially with P. falciparum infections [30].

More generally, it should be noted that PCR could be more relevant as a reference method for the evaluation of non-microscope procedures like RDTs [8, 14, 31], but the indicators still need to be considered with reference to EM, for inter-study comparisons.

RDTs generally achieve a sensitivity of > 90% at densities above 100 parasites per μL of blood, and the sensitivity decreases markedly below that level of parasite density.

The low number of P. falciparum infections in this study could explain the low Parascreen™ sensitivity for P. falciparum infections, as well as the sensitivity discrepancies when using EM and/or PCR as gold standards. Other possible factors, could consist in the genetic diversity of the parasite antigen HRP-2 [32], the existence of parasites that do not carry the pfhrp2 gene in this region [17, 33] and the lack of monoclonal antibodies specificity used by the RDT to detect the HRP- 2 antigen [34]. When this study was carried out in 2006, and this RDT chosen for validation, the existence of P. falciparum isolates lacking the pfhrp2 gene in this region was still unknown and unpredictable, but now this recent discovery has to be taken into account when interpreting results of RDT evaluation studies in general.

Conclusions

The present study showed that Parascreen™ sensitivity was comparable to EM and PCR at parasitaemia levels ≥100 parasites/μl in P. vivax infections and ≥1,000 parasites/μl for P. falciparum infections. In general, Parascreen™ sensitivity was low for Plasmodium infections, especially for fatal infections like P. falciparum. This RDT was not acceptable for malaria diagnosis under the field conditions found in the Peruvian Amazon, even though it was easy to learn and to use by the local health staff. The choice of a RDT for Amazonian countries such as Peru, should consider the local malaria incidence and predominance of Plasmodium species, as well as the genetic characteristics of the parasites, especially the existence in this region of P. falciparum field isolates lacking the pfhrp2 gene.

Declarations

Acknowledgements

This study was supported by The Global Fund to fight AIDS, Tuberculosis and Malaria ™ through the - Organismo Andino de Salud - Convenio Hipolito Unanue' (Principal Recipient of the Multi-Country Malaria Project "Malaria control on the cross border areas of the Andean Region: A community based approach"-PAMAFRO), Grant Number MAA-305-G01-M; and by the Directorate General for Development Cooperation (DGCD) of the Belgian Government (framework agreement 02, 2003-2007), project 95501. DG is supported by DGCD (Framework Agreement 03, 2008-2010, project 910000) and U.S Public Health Service grant NIH/NIAID RO1 AI067727. Additional thanks to Dr. David Bell and Dr. Sandra Incardona for reviewing this manuscript.

Authors’ Affiliations

(1)
Instituto de Medicina Tropical "Alexander Von Humboldt", Universidad Peruana Cayetano Heredia
(2)
Multi-Country Malaria Project "Malaria control on the cross border areas of the Andean Region: A community based approach"-PAMAFRO, Organismo Andino de Salud - Convenio Hipolito Unanue
(3)
Direccion Regional de Salud de Loreto, Ministerio de Salud del Peru
(4)
Departamento de Bioquímica, Biología Molecular y Farmacología, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia

References

  1. World Health Organization: World Malaria Report. Geneva. 2009Google Scholar
  2. Ministerio de Salud: Boletin Epidemiologico. Lima. 2008, 18-[http://www.dge.gob.pe]Google Scholar
  3. Arróspide N: Tratamiento Presuntivo de malaria por promotores de salud en comunidades periurbanas de Iquitos. Rev Peru Med Exp Salud Publica. 2005, 22: 241-242.Google Scholar
  4. Durand S, Cesar R, Maria H, Cabezas C: Oportunidad en el diagnostico y tratamiento de la Malaria en comunidades periurbanas de la Amazonia Peruana. Rev Peru Med Exp Salud Publica. 2005, 22: 47-53.Google Scholar
  5. Bell DR, Wilson DW, Martin LB: False-positive results of a Plasmodium falciparum histidine-rich protein 2-detecting malaria rapid diagnostic test due to high sensitivity in a community with fluctuating low parasite density. Am J Trop Med Hyg. 2005, 73: 199-203.PubMedGoogle Scholar
  6. Cabezas C, Arróspide N, Marquiño W, Gutiérrez S, Álvarez E, Chuquipiondo J, Ruiz T: Evaluación del uso de una prueba rápida inmunocromatográfica en promotores de salud para el diagnóstico de la malaria en áreas rurales de la Amazonia peruana. Rev Peru Med Exp Salud Publica. 2004, 21: 4-11.Google Scholar
  7. Moody A: Rapid diagnostic tests for malaria parasites. Clin Microbiol Rev. 2002, 15: 66-78. 10.1128/CMR.15.1.66-78.2002.PubMed CentralView ArticlePubMedGoogle Scholar
  8. Tham JM, Lee SH, Tan TM, Ting RC, Kara UA: Detection and species determination of malaria parasites by PCR: comparison with microscopy and with ParaSight-F and ICT malaria Pf tests in a clinical environment. J Clin Microbiol. 1999, 37: 1269-1273.PubMed CentralPubMedGoogle Scholar
  9. Kochar DK, Das A, Kochar SK, Saxena V, Sirohi P, Garg S, Kochar A, Khatri MP, Gupta V: Severe Plasmodium vivax malaria: a report on serial cases from Bikaner in northwestern India. Am J Trop Med Hyg. 2009, 80: 194-198.PubMedGoogle Scholar
  10. Arróspide N, Puray M, Guzman E, Verano M, Gutierrez S, Medina S, Gonzales S: Uso de pruebas rápidas inmunocromatográficas para la detección de Plasmodium falciparum en donantes de sangre en Perú. Rev peru Med Exp salud publica. 2004, 21: 76-81.Google Scholar
  11. Iqbal J, Muneer A, Khalid N, Ahmed MA: Performance of the OptiMAL test for malaria diagnosis among suspected malaria patients at the rural health centers. Am J Trop Med Hyg. 2003, 68: 624-628.PubMedGoogle Scholar
  12. Llanos L, Huayta E, Mendoza D, Rosas A, Contreras C, Peinado J: Conocimientos y percepciones de los trabajadores de salud de una zona endémica de malaria en el Perú sobre la prueba de diagnóstico rápido ParaSight-F. Rev Med Hered. 2000, 11: 115-121.Google Scholar
  13. Arróspide N, Puray M, Guzmán E, Verano M, Medina S, A LM, G SG: Estudio multicentrico de DIAMED OptiMAL para el diagnostico de P. falciparum y P. vivax en áreas endémicas del Perú. Rev Peru Med Exp Salud Pública. 2001, 19: 76-81.Google Scholar
  14. Coleman RE, Sattabongkot J, Promstaporm S, Maneechai N, Tippayachai B, Kengluecha A, Rachapaew N, Zollner G, Miller RS, Vaughan JA, Thimasarn K, Khuntirat B: Comparison of PCR and microscopy for the detection of asymptomatic malaria in a Plasmodium falciparum/vivax endemic area in Thailand. Malar J. 2006, 5: 121-10.1186/1475-2875-5-121.PubMed CentralView ArticlePubMedGoogle Scholar
  15. Tjitra E, Suprianto S, Dyer M, Currie BJ, Anstey NM: Field evaluation of the ICT malaria P.f/P.v immunochromatographic test for detection of Plasmodium falciparum and Plasmodium vivax in patients with a presumptive clinical diagnosis of malaria in eastern Indonesia. J Clin Microbiol. 1999, 37: 2412-2417.PubMed CentralPubMedGoogle Scholar
  16. World Health Organization: Malaria Rapid Diagnostic Test Performance: Results of WHO product testing of malaria RDTs: Round 2 (2009). Geneva. 2009, [http://www.finddiagnostics.org/programs/malaria/publications.jsp?year=2009]Google Scholar
  17. Gamboa D, Ho MF, Bendezu J, Torres K, Chiodini PL, Barnwell JW, Incardona S, Perkins M, Bell D, McCarthy J, Cheng Q: A large proportion of P. falciparum isolates in the Amazon region of Peru lack pf hrp2 and pf hrp3: implications for malaria rapid diagnostic tests. PloS One. 5: e8091-10.1371/journal.pone.0008091.Google Scholar
  18. van den Broek I, Hill O, Gordillo F, Angarita B, Hamade P, Counihan H, Guthmann JP: Evaluation of three rapid tests for diagnosis of P. falciparum and P. vivax malaria in Colombia. Am J Trop Med Hyg. 2006, 75: 1209-1215.PubMedGoogle Scholar
  19. Mens P, Spieker N, Omar S, Heijnen M, Schallig H, Kager PA: Is molecular biology the best alternative for diagnosis of malaria to microscopy? A comparison between microscopy, antigen detection and molecular tests in rural Kenya and urban Tanzania. Trop Med Int Health. 2007, 12: 238-244.PubMedGoogle Scholar
  20. Endeshaw T, Gebre T, Ngondi J, Graves PM, Shargie EB, Ejigsemahu Y, Ayele B, Yohannes G, Teferi T, Messele A, Zerihun M, Genet A, Mosher AW, Emerson PM, Richards FO: Evaluation of light microscopy and rapid diagnostic test for the detection of malaria under operational field conditions: a household survey in Ethiopia. Malar J. 2008, 7: 118-10.1186/1475-2875-7-118.PubMed CentralView ArticlePubMedGoogle Scholar
  21. Rajendran C, Dube S: Field evaluation of a rapid immunochromatographic test kit for the diagnosis of Plasmodium falciparum and non-falciparum malaria parasites from Sonitpur district, Assam. Journal of Parasitic Diseases. 2006, 30: 94-97.Google Scholar
  22. Ministerio de Salud: Manual de Procedimientos de Laboratorio para el Diagnóstico de Malaria. Serie de Normas Técnicas 39 Lima;. 2003Google Scholar
  23. PARASCREEN®. Rapid Test for Malaria Pan/Pf (Device). [http://www.tulipgroup.com/Zephyr/html/1_productspecs/1_parascreen.htm]
  24. Rubio JM, Benito A, Roche J, Berzosa PJ, Garcia ML, Mico M, Edu M, Alvar J: Semi-nested, multiplex polymerase chain reaction for detection of human malaria parasites and evidence of Plasmodium vivax infection in Equatorial Guinea. Am J Trop Med Hyg. 1999, 60: 183-187.PubMedGoogle Scholar
  25. Arróspide N, Flores R, Ruíz J: Evaluación de una prueba rápida para el diagnóstico de malaria en áreas endémicas del Perú. Rev Peru Med Exp Salud Publica. 2006, 23: 81-86.Google Scholar
  26. Tarazona AS, Zerpa LS, Requena DM, Llanos-Cuentas A, Magill A: Evaluation of the Rapid Diagnostic Test OptiMAL for Diagnosis of Malaria due to Plasmodium vivax. Brazilian Journal of Infectious Diseases. 2004, 8: 151-155. 10.1590/S1413-86702004000200005.View ArticleGoogle Scholar
  27. Rodulfo H, Donato MD, Mora R, González L, Contreras CE: Comparison of the diagnosis of malaria by microscopy, immunochromatography and PCR in endemic areas of Venezuela. Braz J Med Biol Res. 2007, 40: 535-543. 10.1590/S0100-879X2007000400012.View ArticlePubMedGoogle Scholar
  28. Pabón A, Álvarez G, Yánez J, Céspedes C, Rodríguez Y, Restrepo Á, Blair S: Evaluación de la prueba rápida inmunocromatográfica Binax NOW® ICT Pf/Pv para el diagnóstico del paludismo en un área endémica de Colombia. Biomedica. 2007, 27: 225-235.View ArticlePubMedGoogle Scholar
  29. Marx A, Pewsner D, Egger M, Nuesch R, Bucher HC, Genton B, Hatz C, Juni P: Meta-analysis: accuracy of rapid tests for malaria in travelers returning from endemic areas. Ann Int Med. 2005, 142: 836-846.View ArticlePubMedGoogle Scholar
  30. Playford EG, Walker J: Evaluation of the ICT malaria P.f/P.v and the OptiMal rapid diagnostic tests for malaria in febrile returned travellers. J Clin Microbiol. 2002, 40: 4166-4171. 10.1128/JCM.40.11.4166-4171.2002.PubMed CentralView ArticlePubMedGoogle Scholar
  31. Bejon P, Andrews L, Hunt-Cooke A, Sanderson F, Gilbert SC, Hill AV: Thick blood film examination for Plasmodium falciparum malaria has reduced sensitivity and underestimates parasite density. Malar J. 2006, 5: 104-10.1186/1475-2875-5-104.PubMed CentralView ArticlePubMedGoogle Scholar
  32. Baker J, McCarthy J, Gatton M, Kyle DE, Belizario V, Luchavez J, Bell D, Cheng Q: Genetic diversity of Plasmodium falciparum histidine-rich protein 2 (PfHRP2) and its effect on the performance of PfHRP2-based rapid diagnostic tests. J Inf Dis. 2005, 192: 870-877. 10.1086/432010.View ArticleGoogle Scholar
  33. Llanos-Zavalaga F, Villacorta J, Reyes R, Lecca L, Mendoza D, Mayca J, Velásquez JE: Evaluación de la prueba ICT MALARIA P. f/P.v (AMRAD®) para la detección de P. falciparum y P. vivax en una zona endémica de la Amazonía Peruana. Rev Peru Med Exp Salud Publica. 2002, 19: 39-42.Google Scholar
  34. Lee N, Baker J, Andrews KT, Gatton ML, Bell D, Cheng Q, McCarthy J: Effect of sequence variation in Plasmodium falciparum histidine-rich protein 2 on binding of specific monoclonal antibodies: Implications for rapid diagnostic tests for malaria. J Clin Microbiol. 2006, 44: 2773-2778. 10.1128/JCM.02557-05.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Bendezu et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Advertisement